Molecular Partners AG (MOLN.SW)
CHF 4.83
(4.43%)
CHF 4.83
(4.43%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -1.89 CHF | -152.07% |
| 2022 | 3.63 CHF | 276.21% |
| 2021 | -2.06 CHF | 17.93% |
| 2020 | -2.51 CHF | -48.52% |
| 2019 | -1.69 CHF | 3.43% |
| 2018 | -1.75 CHF | -43.44% |
| 2017 | -1.22 CHF | -34.07% |
| 2016 | -0.91 CHF | -11873.68% |
| 2015 | -0.01 CHF | 94.93% |
| 2014 | -0.15 CHF | -140.54% |
| 2013 | 0.37 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q1 | -0.34 CHF | 43.33% |
| 2024 Q3 | -0.49 CHF | -8.89% |
| 2024 Q2 | -0.45 CHF | -32.35% |
| 2023 Q2 | -0.49 CHF | -4.26% |
| 2023 Q1 | -0.47 CHF | 17.54% |
| 2023 Q4 | -0.60 CHF | -71.43% |
| 2023 Q3 | -0.35 CHF | 28.57% |
| 2023 FY | - CHF | -152.07% |
| 2022 Q3 | -0.37 CHF | -351.22% |
| 2022 Q1 | 4.74 CHF | 723.68% |
| 2022 FY | - CHF | 276.21% |
| 2022 Q4 | -0.57 CHF | -54.05% |
| 2022 Q2 | -0.08 CHF | -101.73% |
| 2021 Q1 | -0.57 CHF | 33.72% |
| 2021 Q2 | -0.56 CHF | 1.75% |
| 2021 FY | - CHF | 17.93% |
| 2021 Q4 | -0.76 CHF | -100.0% |
| 2021 Q3 | -0.38 CHF | 32.14% |
| 2020 Q2 | -0.52 CHF | 16.13% |
| 2020 Q3 | -0.60 CHF | -15.38% |
| 2020 FY | - CHF | -48.52% |
| 2020 Q1 | -0.62 CHF | -12.73% |
| 2020 Q4 | -0.86 CHF | -43.33% |
| 2019 Q2 | -0.30 CHF | 0.0% |
| 2019 FY | - CHF | 3.43% |
| 2019 Q4 | -0.55 CHF | 0.0% |
| 2019 Q3 | -0.55 CHF | -83.33% |
| 2019 Q1 | -0.30 CHF | 50.0% |
| 2018 Q4 | -0.60 CHF | 0.0% |
| 2018 FY | - CHF | -43.44% |
| 2018 Q1 | -0.28 CHF | -100.0% |
| 2018 Q2 | -0.28 CHF | 0.0% |
| 2018 Q3 | -0.60 CHF | -114.29% |
| 2017 Q3 | -0.14 CHF | 75.0% |
| 2017 FY | - CHF | -34.07% |
| 2017 Q4 | -0.14 CHF | 0.0% |
| 2017 Q2 | -0.56 CHF | -51.35% |
| 2017 Q1 | -0.37 CHF | -105.56% |
| 2016 Q3 | -0.25 CHF | 7.41% |
| 2016 Q4 | -0.18 CHF | 28.0% |
| 2016 FY | - CHF | -11873.68% |
| 2016 Q1 | -0.21 CHF | -452.94% |
| 2016 Q2 | -0.27 CHF | -28.57% |
| 2015 Q3 | 0.25 CHF | 208.7% |
| 2015 Q2 | -0.23 CHF | -76.92% |
| 2015 FY | - CHF | 94.93% |
| 2015 Q1 | -0.13 CHF | 53.57% |
| 2015 Q4 | 0.06 CHF | -76.2% |
| 2014 Q4 | -0.28 CHF | -524.24% |
| 2014 Q3 | 0.07 CHF | 45.05% |
| 2014 Q2 | 0.05 CHF | 0.0% |
| 2014 Q1 | 0.05 CHF | 221.98% |
| 2014 FY | - CHF | -140.54% |
| 2013 Q2 | 0.09 CHF | 0.0% |
| 2013 FY | - CHF | 0.0% |
| 2013 Q1 | 0.09 CHF | 0.0% |
| 2013 Q4 | -0.04 CHF | -140.72% |
| 2013 Q3 | 0.09 CHF | 0.0% |
| 2012 Q4 | 0.09 CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Addex Therapeutics Ltd | -0.14 CHF | -1250.0% |
| BB Biotech AG | -3.77 CHF | 49.867% |
| Basilea Pharmaceutica AG | 0.87 CHF | 317.241% |
| Evolva Holding SA | -19.50 CHF | 90.308% |
| Idorsia Ltd | -1.67 CHF | -13.174% |
| Kuros Biosciences AG | -0.38 CHF | -397.368% |
| Relief Therapeutics Holding AG | -8.35 CHF | 77.365% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 136.486% |